Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.65 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.65 |
| ▸ | ITGAL | P20701 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA6 | P23280 | 1/20 | 0.65 |
| ▸ | AHR | P35869 | 1/20 | 0.65 |
| ▸ | ADK | P55263 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | WNT3A | P56704 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole SCHEMBL31119874 | 1.00 | TRPA1 (0.65) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL15552 | 0.92 | TRPA1 (0.71) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL28064106 | 0.92 | TRPA1 (0.71) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL8692212 | 0.92 | TRPA1 (0.71) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL14576595 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL14576774 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL14576591 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL14576309 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL14576777 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 | |
| Naphthalene SCHEMBL29066893 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3690042-B1 | PARTHENOCARPY REGULATION GENE AND USE THEREOF | NATIONAL RES AND DEVELOPMENT AGENCY NATIONAL AGRICULTURE AND FOOD RES ORGANIZATION (JP) | 2026-05-06 | — | — | EP | claimed |
| EP-3796922-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SELENO AMINO ACID COMPOUND FOR USE IN COMBINATION WITH ANOTHER AGENT FOR THE TREATMENT OF LIVER OR PANCREAS CANCER | SELEQ OY (FI) | 2026-03-18 | — | — | EP | claimed |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | SELEQ OY (FI) | 2025-05-27 | — | — | US | claimed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-118486893-A | Amino acid eutectic electrolyte, and preparation method and application thereof | 江苏蓝固新能源科技有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-114674956-A | Application of urine biomarker detection reagent in preparation of kit for predicting neuropsychiatric sequelae of new coronary pneumonia | 重庆医科大学附属第一医院 | 2022-06-28 | — | — | CN | claimed |
| EP-3095863-B1 | PARTHENOCARPY REGULATION GENE AND USE THEREOF | NATIONAL RES AND DEVELOPMENT AGENCY NATIONAL AGRICULTURE AND FOOD RES ORGANIZATION (JP) | 2022-03-09 | — | — | EP | claimed |
| US-11091773-B2 | Parthenocarpy regulation gene and use thereof | NATIONAL RESEARCH AND DEVELOPMENT AGENCY NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (JP) | 2021-08-17 | — | — | US | claimed |
| US-20210220310-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | SELEQ OY (FI) | 2021-07-22 | — | — | US | claimed |
| EP-3796922-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | Seleq Oy (FI) | 2021-03-31 | — | — | EP | claimed |
| WO-2009144699-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-12-03 | — | — | WO | claimed |
| US-20090011476-A1 | GENE CLUSTER AND METHOD FOR THE BIOSYNTHESIS OF TERREQUINONE A | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2009-01-08 | — | — | US | claimed |
| EP-2007206-A2 | METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMINE LEVELS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105203-A2 | METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMATE LEVELS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-09-20 | — | — | WO | claimed |
| US-20060024284-A1 | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-02-02 | — | — | US | claimed |
| EP-1524989-A2 | METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMATE LEVELS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2005-04-27 | — | — | EP | claimed |
| WO-2004012762-A2 | METHOD AND COMPOSITION FOR PROTECTING NEURONAL TISSUE FROM DAMAGE INDUCED BY ELEVATED GLUTAMATE LEVELS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-02-12 | — | — | WO | claimed |
| US-4859591-A | Transamination process for producing amino acids | W. R. GRACE & CO.-CONN. (US) | 1989-08-22 | — | — | US | claimed |
| EP-0162920-A1 | METHOD OF CATALYZING CHEMICAL REACTIONS | IGEN, INC. (a California corporation) (US) | 1985-12-04 | — | — | EP | claimed |
| WO-1985002414-A1 | METHOD OF CATALYZING CHEMICAL REACTIONS | IGEN, INC. (US) | 1985-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220310-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | RNASE1, SELENOI, GLS2 | TRPA1 4500/4885CA1 1479/4885CA2 3013/4885 |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | RNASE1, SELENOI, GLS2 | TRPA1 4500/4885CA1 1479/4885CA2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.